Forward Pharma A/S is a Danish biopharmaceutical company that from 2005 to 2017 developed a proprietary formulation of DMF for the treatment of inflammatory and neurological indications. The Company granted to Biogen an irrevocable license to all of its IP through the License Agreement and received from Biogen a non-refundable cash fee of $1.25 billion in February 2017, with the return of EUR 917.7 million to shareholders through a capital reduction in September 2017.
On 08 January 2024, Forward Pharma announced that the ADR facility will be terminated effective at 5:00 PM (Eastern Time) on February 5, 2024.
Kindly see additional information at the website of the Depositary Bank of New York Mellon (https://www.adrbnymellon.com/files/ad1136444.pdf).
Company Details
- Employees
- 5
- Founded
- -
- Address
- Østergade 24a, 1., København K,capital Region 1100,denmark
- Phone
- +45 33 44 42 42
- in****@****rma.com
- Industry
- Biotechnology
- Website
- forward-pharma.com
- HQ
- København K, Capital Region
Forward Pharma A/s Questions
Forward Pharma A/S's helpline number is +45 33 44 42 42
Forward Pharma A/S's website is forward-pharma.com
Forward Pharma A/S's LinkedIn profile is https://dk.linkedin.com/company/forward-pharma-a-s
Forward Pharma A/S has
5 employees.
View email and phone details for 5
employees at Forward Pharma A/S.
Forward Pharma A/S's industry is
Biotechnology
Forward Pharma A/S's top competitors are
Gh Research Plc,
Nb Capital Aps,
Spot-On Pharma Consulting,
Avilex Pharma Aps,
Initiator Pharma,
Rosco Diagnostica,
Cytoki Pharma,
Aristo Pharma Nordic Aps,
Xenia Pharma,
Medtrace Pharma A/s.
Forward Pharma A/S's support email address is info@forward-pharma.com
Forward Pharma A/S's categories are Biotechnology
Forward Pharma A/S's founding year is 2005
